SIRPA and neoplasm: Previous evidence also reveals that CD47 inhibitor, namely the engineered SIRPα variant CV1 significantly in combination with IgG4 phagocytosis inducer increased the phagocytic activity of macrophages and suppressed tumor growth of xenografts in mice [193].